Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
ABSTRACT Background Lung cancer treatment has rapidly advanced, particularly with immune checkpoint inhibitors (ICIs) targeting PD‐1 and PD‐L1. However, there are variable responses, such as immune‐related adverse events. Several factors predicting the prognosis of lung cancer ICI treatment have bee...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70826 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850144418665857024 |
|---|---|
| author | Green Hong Song‐I Lee Da Hyun Kang Chaeuk Chung Hee Sun Park Jeong Eun Lee |
| author_facet | Green Hong Song‐I Lee Da Hyun Kang Chaeuk Chung Hee Sun Park Jeong Eun Lee |
| author_sort | Green Hong |
| collection | DOAJ |
| description | ABSTRACT Background Lung cancer treatment has rapidly advanced, particularly with immune checkpoint inhibitors (ICIs) targeting PD‐1 and PD‐L1. However, there are variable responses, such as immune‐related adverse events. Several factors predicting the prognosis of lung cancer ICI treatment have been studied so far, but they have limitations, leaving an unmet need. This study aims to investigate delta‐He, a novel marker reflecting the iron availability and inflammation through the difference in hemoglobin content between reticulocytes and erythrocytes, as a potential prognostic factor in patients with NSCLC undergoing PD‐1/PD‐L1 inhibitor therapy. Methods This research was conducted at Chungnam National University Hospital, analyzing 79 advanced NSCLC patients treated with PD‐1/PD‐L1 inhibitors. The study population had a mean age of 70 years, with the majority being male (82.3%) and former or current smokers (84.8%). Blood samples collected before therapy initiation were examined for hematological parameters, including delta‐He, using Sysmex XN‐550 and XN‐20 analyzers. The study employed receiver operating characteristic (ROC) curves and Kaplan–Meier curves for the statistical analysis, using SPSS version 26 (IBM Corp., USA) and MedCalc version 22 (MedCalc Software Ltd., Belgium) to evaluate the sensitivity and specificity of delta‐He, and to analyze progression‐free survival (PFS) and overall survival (OS). Results The study revealed that delta‐He is a significant prognostic marker in patients with NSCLC treated with PD‐1/PD‐L1 inhibitors. A delta‐He cutoff value of 3.3 pg was identified based on ROC analysis. Patients with high delta‐He values (> 3.3 pg) showed significantly longer median PFS (9.6 vs. 3.0 months, p = 0.024) and OS (not reached vs. 12.2 months, p = 0.010) than those with low values. The high delta‐He group also had higher objective response rate (41.4% vs. 26.0%) and disease control rate (86.2% vs. 52.0%). Multivariate analysis highlighted higher delta‐He (> 3.3 pg), along with other factors such as FEV1 and smoking status, as important predictors of survival, underscoring its potential role in guiding therapeutic decisions of ICIs in NSCLC (PFS: HR 0.874, 95% CI 0.264‐0.874, p = 0.016; OS: HR 0.327, 95% CI 0.150‐0.715, p = 0.005). Conclusion Our study shows delta‐He as a promising prognostic biomarker for lung cancer patients treated with PD‐1/PD‐L1 inhibitors, highlighting its potential to guide therapeutic decisions and improve patient management in a non‐invasive manner. Further research is necessary to validate delta‐He's predictive and prognostic value across broader populations and in combination with other biomarkers, emphasizing its role in advancing personalized oncology. |
| format | Article |
| id | doaj-art-40ac265cd58b4c6cbd3f2b71b7a3a431 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-40ac265cd58b4c6cbd3f2b71b7a3a4312025-08-20T02:28:23ZengWileyCancer Medicine2045-76342025-04-01147n/an/a10.1002/cam4.70826Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 InhibitorsGreen Hong0Song‐I Lee1Da Hyun Kang2Chaeuk Chung3Hee Sun Park4Jeong Eun Lee5Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine Chungnam National University Hospital, Chungnam National University School of Medicine Daejeon Republic of KoreaDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine Chungnam National University Hospital, Chungnam National University School of Medicine Daejeon Republic of KoreaDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine Chungnam National University Hospital, Chungnam National University School of Medicine Daejeon Republic of KoreaDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine Chungnam National University Hospital, Chungnam National University School of Medicine Daejeon Republic of KoreaDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine Chungnam National University Hospital, Chungnam National University School of Medicine Daejeon Republic of KoreaDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Internal Medicine Chungnam National University Hospital, Chungnam National University School of Medicine Daejeon Republic of KoreaABSTRACT Background Lung cancer treatment has rapidly advanced, particularly with immune checkpoint inhibitors (ICIs) targeting PD‐1 and PD‐L1. However, there are variable responses, such as immune‐related adverse events. Several factors predicting the prognosis of lung cancer ICI treatment have been studied so far, but they have limitations, leaving an unmet need. This study aims to investigate delta‐He, a novel marker reflecting the iron availability and inflammation through the difference in hemoglobin content between reticulocytes and erythrocytes, as a potential prognostic factor in patients with NSCLC undergoing PD‐1/PD‐L1 inhibitor therapy. Methods This research was conducted at Chungnam National University Hospital, analyzing 79 advanced NSCLC patients treated with PD‐1/PD‐L1 inhibitors. The study population had a mean age of 70 years, with the majority being male (82.3%) and former or current smokers (84.8%). Blood samples collected before therapy initiation were examined for hematological parameters, including delta‐He, using Sysmex XN‐550 and XN‐20 analyzers. The study employed receiver operating characteristic (ROC) curves and Kaplan–Meier curves for the statistical analysis, using SPSS version 26 (IBM Corp., USA) and MedCalc version 22 (MedCalc Software Ltd., Belgium) to evaluate the sensitivity and specificity of delta‐He, and to analyze progression‐free survival (PFS) and overall survival (OS). Results The study revealed that delta‐He is a significant prognostic marker in patients with NSCLC treated with PD‐1/PD‐L1 inhibitors. A delta‐He cutoff value of 3.3 pg was identified based on ROC analysis. Patients with high delta‐He values (> 3.3 pg) showed significantly longer median PFS (9.6 vs. 3.0 months, p = 0.024) and OS (not reached vs. 12.2 months, p = 0.010) than those with low values. The high delta‐He group also had higher objective response rate (41.4% vs. 26.0%) and disease control rate (86.2% vs. 52.0%). Multivariate analysis highlighted higher delta‐He (> 3.3 pg), along with other factors such as FEV1 and smoking status, as important predictors of survival, underscoring its potential role in guiding therapeutic decisions of ICIs in NSCLC (PFS: HR 0.874, 95% CI 0.264‐0.874, p = 0.016; OS: HR 0.327, 95% CI 0.150‐0.715, p = 0.005). Conclusion Our study shows delta‐He as a promising prognostic biomarker for lung cancer patients treated with PD‐1/PD‐L1 inhibitors, highlighting its potential to guide therapeutic decisions and improve patient management in a non‐invasive manner. Further research is necessary to validate delta‐He's predictive and prognostic value across broader populations and in combination with other biomarkers, emphasizing its role in advancing personalized oncology.https://doi.org/10.1002/cam4.70826Delta‐heimmune checkpoint inhibitorsNSCLCPD‐1/PD‐L1 inhibitors |
| spellingShingle | Green Hong Song‐I Lee Da Hyun Kang Chaeuk Chung Hee Sun Park Jeong Eun Lee Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors Cancer Medicine Delta‐he immune checkpoint inhibitors NSCLC PD‐1/PD‐L1 inhibitors |
| title | Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors |
| title_full | Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors |
| title_fullStr | Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors |
| title_full_unstemmed | Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors |
| title_short | Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors |
| title_sort | delta he as a novel predictive and prognostic biomarker in patients with nsclc treated with pd 1 pd l1 inhibitors |
| topic | Delta‐he immune checkpoint inhibitors NSCLC PD‐1/PD‐L1 inhibitors |
| url | https://doi.org/10.1002/cam4.70826 |
| work_keys_str_mv | AT greenhong deltaheasanovelpredictiveandprognosticbiomarkerinpatientswithnsclctreatedwithpd1pdl1inhibitors AT songilee deltaheasanovelpredictiveandprognosticbiomarkerinpatientswithnsclctreatedwithpd1pdl1inhibitors AT dahyunkang deltaheasanovelpredictiveandprognosticbiomarkerinpatientswithnsclctreatedwithpd1pdl1inhibitors AT chaeukchung deltaheasanovelpredictiveandprognosticbiomarkerinpatientswithnsclctreatedwithpd1pdl1inhibitors AT heesunpark deltaheasanovelpredictiveandprognosticbiomarkerinpatientswithnsclctreatedwithpd1pdl1inhibitors AT jeongeunlee deltaheasanovelpredictiveandprognosticbiomarkerinpatientswithnsclctreatedwithpd1pdl1inhibitors |